0001193125-23-277418.txt : 20231115 0001193125-23-277418.hdr.sgml : 20231115 20231115060458 ACCESSION NUMBER: 0001193125-23-277418 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231115 DATE AS OF CHANGE: 20231115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 231408953 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d850613d8k.htm 8-K 8-K
0001576280 false 0001576280 2023-11-14 2023-11-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 14, 2023

 

 

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38683   45-4139254
(State or other jurisdiction
of incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events.

On November 14, 2023, after a trial in the U.S. District Court for the District of Delaware in the matter of TwinStrand Biosciences, Inc. v. Guardant Health, Inc., C.A. No. 21-1126-GBW-SRF, a jury verdict was entered in favor of plaintiffs, TwinStrand Biosciences, Inc. and the University of Washington (the “Plaintiffs”), and against Guardant Health, Inc. (the “Company”). The jury found that the Company willfully infringed U.S. Patent Nos. 10,287,631 and 10,760,127, and awarded Plaintiffs $83.4 million in damages, representing a 6% royalty on past sales. The Company expects that the district court will enter judgment on the jury’s verdict in the coming weeks, after which the Company will file post-trial motions to overturn the jury’s verdict, seek a new trial, and/or amend the judgment. The Plaintiffs may seek to enhance the damages award up to three times based on the jury’s finding of willful infringement. The Company disagrees strongly with the jury’s findings and plans to vigorously contest the verdict and judgment through post-trial motions in the district court, and through appeal to the U.S. Court of Appeals for the Federal Circuit. The Company does not expect the verdict to materially impact its business, but it may have an impact on future expenses if the verdict is upheld on appeal, as the court may require royalty payments on the Company’s future sales.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press release of Guardant Health, Inc., dated November 15, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GUARDANT HEALTH, INC.
Date: November 15, 2023     By:  

/s/ John G. Saia

      John G. Saia
      Chief Legal Officer and Corporate Secretary
 EX-99.1 2 d850613dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

PRESS RELEASE

Guardant Health to Appeal Federal District Court Verdict

PALO ALTO, Calif. - (BUSINESS WIRE) - (November 15, 2023) – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington.

“We strongly disagree with this decision and will vigorously appeal for its overturn,” said Helmy Eltoukhy, Guardant Health co-founder and co-CEO. “We believe the ruling ignores the strengths and merits of our R&D and intellectual property, which we painstakingly developed for over a decade.”

Guardant remains confident that it did not infringe the asserted patents, and the company expects to file additional motions with the U.S. District Court for the District of Delaware and appeal to the U.S. Court of Appeals for the Federal Circuit.

About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter (X).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and

elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Investor Contact:

investors@guardanthealth.com

Media Contact:

Matt Burns

press@guardanthealth.com

+1 518 423 5907

EX-101.SCH 3 gh-20231114.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 gh-20231114_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 5 gh-20231114_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g850613dsp5a.jpg GRAPHIC begin 644 g850613dsp5a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 14, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 14, 2023
Entity Registrant Name GUARDANT HEALTH, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38683
Entity Tax Identification Number 45-4139254
Entity Address Address Line 1 3100 Hanover Street
Entity Address City Or Town Palo Alto
Entity Address State Or Province CA
Entity Address Postal Zip Code 94304
City Area Code 855
Local Phone Number 698-8887
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value per share
Trading Symbol GH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001576280
Amendment Flag false
XML 8 d850613d8k_htm.xml IDEA: XBRL DOCUMENT 0001576280 2023-11-14 2023-11-14 0001576280 false 8-K 2023-11-14 GUARDANT HEALTH, INC. DE 001-38683 45-4139254 3100 Hanover Street Palo Alto CA 94304 855 698-8887 false false false false Common Stock, $0.00001 par value per share GH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d850613d8k.htm gh-20231114.xsd gh-20231114_lab.xml gh-20231114_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d850613d8k.htm": { "nsprefix": "gh", "nsuri": "http://guardanthealth.com/20231114", "dts": { "inline": { "local": [ "d850613d8k.htm" ] }, "schema": { "local": [ "gh-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "gh-20231114_lab.xml" ] }, "presentationLink": { "local": [ "gh-20231114_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-14_to_2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850613d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-14_to_2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850613d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://guardanthealth.com//20231114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-23-277418-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-277418-xbrl.zip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end